MDGL

Business Context and Reporting Period

Company: Madrigal Pharmaceuticals, Inc. (MDGL)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Madrigal is a biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis (MASH). Its only approved product, Rezdiffra (resmetirom), received FDA accelerated approval in March 2024 and European Commission conditional marketing authorization in August 2025, with a commercial launch in Germany in September 2025. The company is advancing a pipeline of MASH candidates through strategic licensing.

Key Financial Metrics

Note: The filing does not provide explicit gross margin percentages; however, Cost of Sales was $26.8 million for Q1 2026.

Material Changes vs. Prior Period

• Revenue Growth: Net product revenue increased 127% year-over-year to $311.3 million, driven by increased demand for Rezdiffra in the U.S. and the commencement of European sales.
• Expense Expansion: Total operating expenses rose 87% to $404.1 million.
  • R&D: Increased 146% to $108.7 million, primarily due to $54.3 million in one-time upfront payments for business development transactions and increased headcount.
  • SG&A: Increased 60% to $268.5 million, driven by commercial investments (including direct-to-consumer marketing) and expansion of the endocrinology field force.
• Debt Restructuring: In July 2025, the company repaid its prior Hercules Loan Facility ($115.0 million principal) and entered a new Financing Agreement with a $350.0 million initial term loan, increasing interest expense to $7.8 million from $3.3 million.
• Accounting Revision: The company revised its net loss per share calculation to include Pre-Funded Warrants and Series A/B Preferred Stock in the weighted average shares outstanding, reducing the reported loss per share for prior periods.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue incurring losses until revenue from Rezdiffra and future products is sufficient. Cash resources are deemed sufficient to fund operations for at least one year from the filing date.
• Clinical Pipeline:
  • Rezdiffra: MAESTRO-NASH OUTCOMES trial (compensated MASH cirrhosis) results expected in 2027; MAESTRO-NASH outcomes data expected in 2028 to support full FDA approval.
  • New Assets: Recent licenses include ervogastat (Pfizer), six siRNA programs (Ribocure), and ARO-PNPLA3 (Arrowhead). Phase 2 combination trials with Rezdiffra are planned.
• Liquidity Covenants: The new Financing Agreement requires maintaining a minimum unrestricted cash balance of $100.0 million.
• Risks: Key risks include the ability to obtain full regulatory approval for Rezdiffra, market acceptance and reimbursement rates, execution of clinical trials, and the need for additional capital to fund substantial future liquidity requirements.

Investor Verification Checklist

• Revenue Sustainability: Verify the trajectory of Rezdiffra sales growth and the impact of European reimbursement approvals on future revenue.
• One-Time Expenses: Confirm the classification and timing of the $54.3 million in upfront business development payments included in Q1 2026 R&D.
• Cash Burn Rate: Monitor the net cash used in operating activities ($167.4 million in Q1) against the $817.9 million cash balance to assess runway.
• Debt Covenants: Ensure continued compliance with the $100 million minimum unrestricted cash balance covenant under the Blue Owl Financing Agreement.
• Regulatory Milestones: Track the status of the MAESTRO-NASH OUTCOMES trial (2027) and MAESTRO-NASH confirmatory data (2028) critical for full FDA approval.